Abstract A158: Racial and ethnic variation in conversion from actionable Guardant360 results to matched targeted therapy in non–small cell lung cancer: A real-world analysis
Although racial and ethnic disparities in genomic testing access are well documented in non–small cell lung cancer (NSCLC), it remains unknown whether disparities persist downstream in the conversion from an actionable result to matched targeted therapy. This step involves only patients who have already been test...